Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — 9M FY24 Earnings Presentation
39 slides from Rpg Life Sciences's earnings presentation, 2024
Slide 1: Investors' Presentation 9M FY24
Investors’ Presentation 9M FY24
Slide 2: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 3: RPG Group: One of India's fastest-growing diversified conglomerates
RPG Group: One of India's fastest-growing diversified conglomerates RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses in Infrastructure, Technology, Tyres, Life Sciences, and p
Slide 4: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company –APIs to Formulations; R&D to Manufacturing to Marketing RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the Leader in Immunosuppressants
Slide 5: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio: Strong ‘Textbook’ brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies Key Therapies Key Products Legacy Portfolio New Portfolio Nephrology Immunosuppressants Text Book Brands Specialty Chronic Life Cycle Ma
Slide 6: Financial Performance
Financial Performance Z An @>9RPG Company ————— pe iE SCIENCES
Slide 7: Journey of RPG Life Sciences
Journey of RPG Life Sciences 1 2 Process Excellence Product Portfolio, People, Business Processes Fundamentals Fixation Sales Hygiene, People, Organization 3 Sustainable Profitable Growth Revenues, Volumes, Margins 4 Benchmark 5 Performance Profitability, Leverage, Liquidity Ratios Scale-up
Slide 8: Q3 FY24 Performance
Q3 FY24 Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 35.5 153.7 25.7 39.8 130.6 29.7 19.7% 23.1% 25.9% 22.8% Q3 FY23 Q3 FY24 Q3 FY23 Q3 FY24 Q3 FY23 Q3 FY24 PAT & PAT Margin EPS 26.5 16.0 19.1 11.6 17.2% 14.6% Q3 FY23 Q3 FY
Slide 9: 9M FY24 Performance
9M FY24 Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 455.1 394.3 113.0 100.1 89.7 77.9 24.8% 22.0% 22.8% 19.7% 9M FY23 9M FY24 9M FY23 9M FY24 9M FY23 9M FY24 PAT & PAT Margin EPS 74.4 45.0 57.3 34.6 16.4% 14.5% 9M FY23 9M
Slide 10: 9M FY24: 5 Year Trends- Key Financials
9M FY24: 5 Year Trends- Key Financials (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 107.5 113.0 512.8 100.1 440.2 455.1 89.4 91.7 375.6 389.1 70.8 73.2 330.2 59.9 53.6 34.4 41.8 15.1 10.4% 15.9% 18.2% 20.3% 21.0% 24.8% 4.6% 11.1% 13.8%
Slide 11: 5Y Trajectory of Uninterrupted Margins Expansion
9MFY24: 5Y Trajectory of Uninterrupted Margins Expansion continues despite Market Challenges EBITDA% 24.8% 20.3% PBT% 21.0% 22.0% 18.2% 16.6% 17.9% PAT% 15.9% 16.4% 13.8% 11.7% 13.2% 11.1% 11.1% 10.4% 10.3% 9.8% 9.3% 8.1% 8.7% 7.7% 6.2% 6.0% 5.9% 4.7% 4.6% 4.2% 4.2% 0.9% 0.2% 0.4% 3.9% 3.9% 3.3% 0.4
Slide 12: 5 Year Trends- Key Ratios (ROCE, ROE, D/E)
5 Year Trends- Key Ratios (ROCE, ROE, D/E) ROCE% ROE% Debt/Equity Ratio 22.0% 0.22 24.9% 28.5% 29.7% 18.5% 20.1% 16.4% 20.9% 9.7% 6.7% 0.06 0.01 0.00 0.00 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Company continues to remain Debt-free 12
Slide 13: 9M FY24: Business Segment-wise Performance
9M FY24: Business Segment-wise Performance Domestic Formulations contributed 66% to total sales of 9M FY24 298.2 • 16% sales growth driven by both Legacy and New products 256.7 Domestic • Growth consistently higher than the market Business Segments Formulations • New products* contribution improving
Slide 14: RPG Life Sciences ICRA Rating Reaffirmed in FY23
RPG Life Sciences ICRA Rating Reaffirmed in FY23 Long term rating reaffirmed at A Short term rating reaffirmed at A1 Outlook on long term rating has been retained as Stable The rating reaffirmation factors: Strong brands in the Indian Pharmaceutical Industry Considerable improvement in the opera
Slide 15: Business Strategy
Business Strategy Z An @>F@P@G Company ———— PG LIFE SCIENCES
Slide 16: Domestic Formulations (DF): Overview and Strategy
Domestic Formulations (DF): Overview and Strategy • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Cust
Slide 17: International Formulations (IF) Business: Overview and Strategy
International Formulations (IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 18: APIs Business: Overview and Strategy
APIs Business: Overview and Strategy • High value, low volume, niche APIs • Footprints across geographies - LATAM, Germany, China, South • Mature stable molecules Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to International • Strong customer focus – long-lasting relat
Slide 19: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities 19
Slide 20: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 21: Strong Backend Capabilities
Strong Backend Capabilities Quality Regulatory • All critical SOPs harmonized through CQA • Well established & evolved Regulatory function catering • Quarterly internal audit of all plants by CQA to Canada, UK, EU, Australia and emerging markets • All critical deviations, change controls and market
Slide 22: Operational Highlights
Operational Highlights An FPG Company
Slide 23: Top Operational Highlights
Top 10 Operational Highlights Strategic Asset (Mega Brand) building via a Comprehensive Life Cycle Legacy Product Naprosyn becomes the first 60 Cr+ Brand of the Company in FY23; On 1 Management Strategy for DF Legacy products yielding results its way to becoming the 1st 100 Cr brand Strategic Portfo
Slide 24: RxR 2.0 for Salesforce Effectiveness; RPG Serv for Doctor Servicing
Glimpses of RPGLS Digitalization Initiatives: Sales & Marketing RxR 2.0 for ↑ Salesforce Effectiveness ; RPG Serv for ↑SoV and ↑Doctor Servicing RxR 2.0: RPGLS Salesforce Effectiveness Automation Tool RPG Serv: Anytime Anywhere Doctor Support Initiative • A suite of Sales Force Automation (SFA) and
Slide 25: LSAI: Using GenAI for Superior Customer Servicing and Marketing
Glimpses of RPGLS Digitalization Initiatives: Sales & Marketing LSAI: Using GenAI for Superior Customer Servicing and impactful Marketing
Slide 26: Roadmap of >20 Initiatives under Implementation
Digitalization Initiatives: Manufacturing and Quality Operations Roadmap of >20 Initiatives under various stages of Implementation Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Implementation •
Slide 27: Innovation Culture @RPGLS
Innovation Culture @RPGLS Innovation Goals Innovation Projects ↑ Revenue Illustrative Projects ↓ Cost # of Innovation Projects: 26 (FY21)→105 (FY22)→ 27 (FY23) → 201 (FY24) ↑ Compliances NapRelief WOMAC Trial : One of the largest Mega Trials conducted in the industry (10200 patients; 458 Doctors; 45
Slide 28: People Initiatives: Building Happy Performance focussed Culture
People Initiatives: Building Happy Performance focussed Culture I Love My Work I Feel Valued RPGLS Heroes I am Growing Outperformance recognition We Skill. You Grow. Competency building You Excel. We Applaud. continuum Motivation continuum Akanksha High Career development Happiness Quotient I Live a
Slide 29: People Initiatives: Building Happy Performance focussed Culture- Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses Hello Happiness Forums: Monthly Townhall for Connect, Recognition and Camaraderie 140+ 100+ Awards Recognitions 1000+ colleagues Celebrated
Slide 30: People Initiatives: Building Happy Performance focussed Culture- Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses Parivar Tyohar Utsav Shrankhla: Virtual Celebration of Festivals with Families
Slide 31: People Initiatives: Building Happy Performance focussed Culture- Glimpses
People Initiatives: Building Happy Performance focussed Culture- Glimpses
Slide 32: Awards & Recognitions
Awards & Recognitions Z An @>9@P@G Company ——————————— PG LIFE SCIENCES
Slide 33: RPG Life Sciences recognized as India's Top Value Creators by Dun & Bradstreet
RPG Life Sciences recognized as India’s Top 500 Value Creators by Dun & Bradstreet
Slide 34: Jamnalal Bajaj Award for Fair Business Practices
RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’ Jamnalal Bajaj Award for Fair Business Practices (2021-22)
Slide 35: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA Industry Recognition to RPG Life Sciences Best Patent Award Best Corporate Citizen Award
Slide 36: New Launch Naprosyn+ bags Brand Champion of the Year Award
New Launch Naprosyn+ bags Brand Champion of the Year Award
Slide 37: Committed to our Transformation Agenda
We are Committed to our Transformation Agenda to continue our upward growth trajectory Profit Growth and Focus on Revenue Growth Strong Governance Cashflows Building Domestic Formulations Business Continued diligent thrust on cost All operations within the via the identified 5 Pillars control measur
Slide 38: The Journey Ahead: 7 Pillars to Scale-up business
The Journey Ahead: Diligent work on-going on 7 Pillars to “Scale-up” business 7 Pillars Identified 1 2 3 4 5 6 7 State-of-art Targeted Lead Therapy Talent Institutionalized TECHNOLOGY ↑ Capacity Niche- focus M&As ADJACENT Development INNOVATION enablement PLANTS R&D PIPELINE Spaces /Acquisition • Fo
Slide 39: An FPG Company RPG LIFE SCIENCES
800006 000 Z An FPG Company RPG LIFE SCIENCES